The renin-angiotensin-aldosterone system: a new look at an old system

[1] PURIFICATION OF HUMAN ANGIOTENSIN [J]. NATURE, 1967, 214 (5085) : 278 - &

[2] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers [J]. HYPERTENSION RESEARCH, 2023, 46 (01) : 108 - 118

[3] A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects [J]. HYPERTENSION RESEARCH, 2010, 33 (10) : 1044 - 1052

[4] Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation [J]. HYPERTENSION RESEARCH, 2004, 27 (10) : 765 - 770

[5] Molecular analysis of the structure and function of the angiotensin II type 1 receptor [J]. HYPERTENSION RESEARCH, 2003, 26 (12) : 937 - 943

[6] The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line [J]. HYPERTENSION RESEARCH, 2016, 39 (11) : 758 - 763

[7] Rakugi H, 2022, HYPERTENS RES, DOI [10.1038/s41440-021-00819-7, 10.1038/541440-021-00819-7]

[8] Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy [J]. HYPERTENSION RESEARCH, 2022, 45 (08) : 1310 - 1321

[9] Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells [J]. HYPERTENSION RESEARCH, 2023, 46 (01) : 40 - 49

[10] Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation [J]. HYPERTENSION RESEARCH, 2009, 32 (07) : 625 - 630

[1] PURIFICATION OF HUMAN ANGIOTENSIN [J]. NATURE, 1967, 214 (5085) : 278 - &

[2] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers [J]. HYPERTENSION RESEARCH, 2023, 46 (01) : 108 - 118

[3] A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects [J]. HYPERTENSION RESEARCH, 2010, 33 (10) : 1044 - 1052

[4] Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation [J]. HYPERTENSION RESEARCH, 2004, 27 (10) : 765 - 770

[5] Molecular analysis of the structure and function of the angiotensin II type 1 receptor [J]. HYPERTENSION RESEARCH, 2003, 26 (12) : 937 - 943

[6] The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line [J]. HYPERTENSION RESEARCH, 2016, 39 (11) : 758 - 763

[7] Rakugi H, 2022, HYPERTENS RES, DOI [10.1038/s41440-021-00819-7, 10.1038/541440-021-00819-7]

[8] Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy [J]. HYPERTENSION RESEARCH, 2022, 45 (08) : 1310 - 1321

[9] Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells [J]. HYPERTENSION RESEARCH, 2023, 46 (01) : 40 - 49

[10] Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation [J]. HYPERTENSION RESEARCH, 2009, 32 (07) : 625 - 630